Could a simple blood test spare lung cancer patients from chemo?

NCT ID NCT06924710

Recruiting now Knowledge-focused Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether people with early-stage lung cancer (stage IA2 to II) who have no detectable cancer DNA in their blood after surgery can safely skip additional treatments like chemotherapy. Instead, they would be closely monitored with regular blood tests and scans. The trial will compare this 'adaptive therapy' approach to standard care to see if it leads to similar survival rates while reducing side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: standard therapy (chemotherapy, immunotherapy, or targeted therapy)
What this could lead to: If successful, this could show that some early-stage lung cancer patients can safely avoid chemotherapy and its side effects by relying on close monitoring.
What could go wrong: This is an early-stage study (Phase NA) with only 286 participants. The approach may not be safe for all patients, and there is a risk that cancer could return without treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

Peking University Cancer Hospital & Institute
RECRUITING

Beijing, Beijing Municipality, 100142, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.